ATAI Life Sciences N.V. Common Shares
ATAI Real Time Price USDRecent trades of ATAI by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ATAI's directors and management
Government lobbying spending instances
-
$20,000 Jul 20, 2022 Issue: None
-
$30,000 Apr 20, 2022 Issue: Pharmacy
-
$50,000 Jan 20, 2022 Issue: Pharmacy
-
$50,000 Oct 20, 2021 Issue: None
-
$15,000 Aug 09, 2021 Issue: Pharmacy Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Aminotetraline activators of serotonin receptors Nov. 28, 2023
-
Patent Title: N,n-dimethyltryptamine compositions and methods Mar. 14, 2023
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ATAI in WallStreetBets Daily Discussion
Recent insights relating to ATAI
Recent picks made for ATAI stock on CNBC
ETFs with the largest estimated holdings in ATAI
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ATAI Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.